New research suggests that the androgens during hormone replacement therapy may play a crucial role in reshaping transgender men’s breast cancer risk.

Hypogonadism in men, involving low testosterone production, results in reduced libido, fatigue, and muscle loss. Diagnosis involves physical exams and testosterone tests. Causes include pituitary ...

International Journal of Impotence Research - Physicians' attitudes towards androgen replacement therapy for male and female sexual dysfunction Skip to main content Thank you for visiting nature.com.

A therapy commonly used for gender affirmation in transgender men potentially could have a role in the development of therapies for ER-positive breast cancer, according to a study published in ...

Testosterone therapy increased median PSA from 3.1 ng/mL to 13.3 ng/mL in the biochemical recurrence group, from 6.3 ng/mL to 17.8 ng/mL in the metastatic prostate cancer group, and from less than ...

Clarus Therapeutics is a commercial stage pharmaceutical company advancing androgen replacement and metabolic therapies. The Company’s lead product JATENZO was FDA approved in March 2019 and ...

Androgen receptor signaling contributes to targeted therapy resistance in melanoma. ScienceDaily . Retrieved May 19, 2025 from www.sciencedaily.com / releases / 2022 / 06 / 220615113257.htm ...

The goal of androgen-deprivation therapy is to suppress testosterone to castrate levels (i.e., <50 ng per deciliter), which is generally achieved within 2 weeks after initiation of therapy with ...

Even after anti-androgen therapy, docetaxel remains useful in prostate cancer. ScienceDaily. Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2016 / 01 / 160111121438.htm.